Skip to menu Skip to content Skip to footer

2025

Journal Article

Overall survival and quality of life with [177Lu]Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer (ENZA-p): secondary outcomes from a multicentre, open-label, randomised, phase 2 trial

Emmett, Louise, Subramaniam, Shalini, Crumbaker, Megan, Joshua, Anthony M, Sandhu, Shahneen, Nguyen, Andrew, Weickhardt, Andrew, Lee, Sze-Ting, Ng, Siobhan, Francis, Roslyn J, Goh, Jeffrey C, Pattison, David A, Tan, Thean Hsiang, Kirkwood, Ian D, Gedye, Craig, Rutherford, Natalie K, Kumar, Aravind S Ravi, Pook, David, Ramdave, Shakher, Nadebaum, David P, Voskoboynik, Mark, Redfern, Andrew D, Macdonald, William, Krieger, Laurence, Schembri, Geoff, Chua, Wei, Lin, Peter, Horvath, Lisa, Bastick, Patricia ... Bills, Madison (2025). Overall survival and quality of life with [177Lu]Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer (ENZA-p): secondary outcomes from a multicentre, open-label, randomised, phase 2 trial. The Lancet Oncology, 26 (3), 291-299. doi: 10.1016/s1470-2045(25)00009-9

Overall survival and quality of life with [177Lu]Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer (ENZA-p): secondary outcomes from a multicentre, open-label, randomised, phase 2 trial

2025

Journal Article

Evaluating the prognostic value of radiomics and clinical features in metastatic prostate cancer using [68Ga]Ga-PSMA-11 PET/CT

Molin, Kaylee, Barry, Nathaniel, Gill, Suki, Hassan, Ghulam Mubashar, Francis, Roslyn J., Ong, Jeremy S. L., Ebert, Martin A. and Kendrick, Jake (2025). Evaluating the prognostic value of radiomics and clinical features in metastatic prostate cancer using [68Ga]Ga-PSMA-11 PET/CT. Physical and Engineering Sciences in Medicine, 1-13. doi: 10.1007/s13246-024-01516-8

Evaluating the prognostic value of radiomics and clinical features in metastatic prostate cancer using [68Ga]Ga-PSMA-11 PET/CT

2025

Journal Article

Outcome prediction based on [18F]FDG PET/CT in patients with pleural mesothelioma treated with ipilimumab and nivolumab +/- UV1 telomerase vaccine

Thunold, Solfrid, Hernes, Eivor, Farooqi, Saima, Öjlert, Åsa Kristina, Francis, Roslyn J., Nowak, Anna K., Szejniuk, Weronika Maria, Nielsen, Søren Steen, Cedres, Susana, Perdigo, Marc Simo, Sørensen, Jens Benn, Meltzer, Carin, Mikalsen, Lars Tore Gyland, Helland, Åslaug, Malinen, Eirik and Haakensen, Vilde Drageset (2025). Outcome prediction based on [18F]FDG PET/CT in patients with pleural mesothelioma treated with ipilimumab and nivolumab +/- UV1 telomerase vaccine. European Journal of Nuclear Medicine and Molecular Imaging, 52 (2), 693-707. doi: 10.1007/s00259-024-06853-0

Outcome prediction based on [18F]FDG PET/CT in patients with pleural mesothelioma treated with ipilimumab and nivolumab +/- UV1 telomerase vaccine

2024

Journal Article

Sequential [177Lu]Lu-PSMA-617 and docetaxel versus docetaxel in patients with metastatic hormone-sensitive prostate cancer (UpFrontPSMA): a multicentre, open-label, randomised, phase 2 study

Azad, Arun A, Bressel, Mathias, Tan, Hsiang, Voskoboynik, Mark, Suder, Aneta, Weickhardt, Andrew J, Guminski, Alexander, Francis, Roslyn J, Saghebi, Javad, Dhiantravan, Nattakorn, Joshua, Anthony M, Emmett, Louise, Horvath, Lisa, Murphy, Declan G, Hsiao, Edward, Balakrishnar, Bavanthi, Lin, Peter, Redfern, Andrew, Macdonald, William, Ng, Siobhan, Lee, Sze-Ting, Pattison, David A, Nadebaum, David, Kirkwood, Ian D, Hofman, Michael S, Akhurst, T, Alipour, R, Au, L, Banks, P ... Ratnayake, L (2024). Sequential [177Lu]Lu-PSMA-617 and docetaxel versus docetaxel in patients with metastatic hormone-sensitive prostate cancer (UpFrontPSMA): a multicentre, open-label, randomised, phase 2 study. The Lancet Oncology, 25 (10), 1267-1276. doi: 10.1016/s1470-2045(24)00440-6

Sequential [177Lu]Lu-PSMA-617 and docetaxel versus docetaxel in patients with metastatic hormone-sensitive prostate cancer (UpFrontPSMA): a multicentre, open-label, randomised, phase 2 study

2024

Journal Article

Assessing the heterogeneity of response of [68Ga] Ga-PSMA-11 PET/CT lesions in patients with biochemical recurrence of prostate cancer

Dell'Oro, Mikaela, Huff, Daniel T., Lokre, Ojaswita, Kendrick, Jake, Munian Govindan, Rajkumar, Ong, Jeremy S. L., Ebert, Martin A., Perk, Timothy G. and Francis, Roslyn J. (2024). Assessing the heterogeneity of response of [68Ga] Ga-PSMA-11 PET/CT lesions in patients with biochemical recurrence of prostate cancer. Clinical Genitourinary Cancer, 22 (5) 102155, 102155. doi: 10.1016/j.clgc.2024.102155

Assessing the heterogeneity of response of [68Ga] Ga-PSMA-11 PET/CT lesions in patients with biochemical recurrence of prostate cancer

2024

Journal Article

Training and assessing convolutional neural network performance in automatic vascular segmentation using Ga-68 DOTATATE PET/CT

Parry, R., Wright, K., Bellinge, J. W., Ebert, M. A., Rowshanfarzad, P., Francis, R. J. and Schultz, C. J. (2024). Training and assessing convolutional neural network performance in automatic vascular segmentation using Ga-68 DOTATATE PET/CT. International Journal of Cardiovascular Imaging, 40 (9), 1847-1861. doi: 10.1007/s10554-024-03171-2

Training and assessing convolutional neural network performance in automatic vascular segmentation using Ga-68 DOTATATE PET/CT

2024

Journal Article

The Australian Traumatic Brain Injury Initiative: systematic review of clinical factors associated with outcomes in people with moderate-severe traumatic brain injury

McKimmie, Ancelin, Keeves, Jemma, Gadowski, Adelle, Bagg, Matthew K., Antonic-Baker, Ana, Hicks, Amelia J., Hill, Regina, Clarke, Nyssa, Holland, Andrew, Veitch, Bill, Fatovich, Daniel, Reeder, Sandy, Romero, Lorena, Ponsford, Jennie L., Lannin, Natasha A., O’Brien, Terence J., Cooper, D. Jamie, Rushworth, Nick, Fitzgerald, Melinda, Gabbe, Belinda J., Cameron, Peter A., Alexander, Tara, Anderson, Vicki, Armstrong, Elizabeth, Babl, Franz E., Balogh, Zsolt J., Barlow, Karen M. (AUS-TBI Investigators member), Bellapart, Judith, Bidargaddi, Niranjan ... Zeeman, Heidi (2024). The Australian Traumatic Brain Injury Initiative: systematic review of clinical factors associated with outcomes in people with moderate-severe traumatic brain injury. Neurotrauma Reports, 5 (1), 640-659. doi: 10.1089/neur.2023.0111

The Australian Traumatic Brain Injury Initiative: systematic review of clinical factors associated with outcomes in people with moderate-severe traumatic brain injury

2024

Journal Article

Clinical trial protocol for PRIMARY2: a multicentre, phase 3, randomised controlled trial investigating the additive diagnostic value of [68Ga]Ga-PSMA-11 positron emission tomography/computed tomography in men with negative or equivocal multiparametric magnetic resonance imaging for the diagnosis of clinically significant prostate cancer

Buteau, James P., Moon, Daniel, Fahey, Michael T., Roberts, Matthew J., Thompson, James, Murphy, Declan G., Papa, Nathan, Mitchell, Catherine, De Abreu Lourenco, Richard, Dhillon, Haryana M., Kasivisvanathan, Veeru, Francis, Roslyn J., Stricker, Phillip, Agrawal, Shihka, O'Brien, Jonathan, McVey, Aoife, Sharma, Gaurav, Levy, Sidney, Ayati, Narjess, Nguyen, Andrew, Lee, Su-Faye, Pattison, David A., Sivaratnam, Dinesh, Frydenberg, Mark, Du, Yang, Titus, Jehan, Lee, Sze-Ting, Ischia, Joseph, Jack, Greg ... Emmett, Louise (2024). Clinical trial protocol for PRIMARY2: a multicentre, phase 3, randomised controlled trial investigating the additive diagnostic value of [68Ga]Ga-PSMA-11 positron emission tomography/computed tomography in men with negative or equivocal multiparametric magnetic resonance imaging for the diagnosis of clinically significant prostate cancer. European Urology Oncology, 7 (3), 544-552. doi: 10.1016/j.euo.2023.11.008

Clinical trial protocol for PRIMARY2: a multicentre, phase 3, randomised controlled trial investigating the additive diagnostic value of [68Ga]Ga-PSMA-11 positron emission tomography/computed tomography in men with negative or equivocal multiparametric magnetic resonance imaging for the diagnosis of clinically significant prostate cancer

2024

Journal Article

An automated radiosynthesis of [68Ga]Ga-FAPI-46 for routine clinical use

Morandeau, Laurence, Ioppolo, Joseph A., Alvarez de Eulate, Eva, Mohamed, Shifaza, Cullen, Danica, Asad, Ali H., Francis, Roslyn J. and Atkinson, Janette (2024). An automated radiosynthesis of [68Ga]Ga-FAPI-46 for routine clinical use. Journal of Visualized Experiments, 2024 (207) e66708. doi: 10.3791/66708

An automated radiosynthesis of [68Ga]Ga-FAPI-46 for routine clinical use

2024

Journal Article

Plasma lipoprotein(a) is associated with calcification activity of the thoracic aorta and aortic valve in statin naïve individuals with diabetes mellitus

Bellinge, Jamie W., Chan, Dick C., Pang, Jing, Francis, Roslyn J., Page, Michael M., Watts, Gerald F. and Schultz, Carl J. (2024). Plasma lipoprotein(a) is associated with calcification activity of the thoracic aorta and aortic valve in statin naïve individuals with diabetes mellitus. European Journal of Clinical Investigation, 54 (5) e14167. doi: 10.1111/eci.14167

Plasma lipoprotein(a) is associated with calcification activity of the thoracic aorta and aortic valve in statin naïve individuals with diabetes mellitus

2024

Journal Article

[177Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial

Emmett, Louise, Subramaniam, Shalini, Crumbaker, Megan, Nguyen, Andrew, Joshua, Anthony M., Weickhardt, Andrew, Lee, Sze-Ting, Ng, Siobhan, Francis, Roslyn J., Goh, Jeffrey C., Pattison, David A., Tan, Thean Hsiang, Kirkwood, Ian D., Gedye, Craig, Rutherford, Natalie K., Sandhu, Shahneen, Kumar, Aravind Ravi, Pook, David, Ramdave, Shakher, Nadebaum, David P., Voskoboynik, Mark, Redfern, Andrew D., Macdonald, William, Krieger, Laurence, Schembri, Geoff, Chua, Wei, Lin, Peter, Horvath, Lisa, Bastick, Patricia ... Davis, Ian D. (2024). [177Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial. The Lancet Oncology, 25 (5), 563-571. doi: 10.1016/s1470-2045(24)00135-9

[177Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial

2024

Journal Article

The prognostic value of F18 Fluorothymidine positron emission tomography for assessing the response of malignant pleural mesothelioma to chemotherapy – a prospective cohort study

May, Isaac J., Nowak, Anna K., Francis, Roslyn J., Ebert, Martin A. and Dhaliwal, Satvinder S. (2024). The prognostic value of F18 Fluorothymidine positron emission tomography for assessing the response of malignant pleural mesothelioma to chemotherapy – a prospective cohort study. Journal of Medical Imaging and Radiation Oncology, 68 (1), 57-66. doi: 10.1111/1754-9485.13592

The prognostic value of F18 Fluorothymidine positron emission tomography for assessing the response of malignant pleural mesothelioma to chemotherapy – a prospective cohort study

2024

Journal Article

The Australian traumatic brain injury initiative: systematic review and consensus process to determine the predictive value of pre-existing health conditions for people with moderate-severe traumatic brain injury

Antonic-Baker, Ana, Auvrez, Clarissa, Tao, Gerard, Bagg, Matthew K., Gadowski, Adelle, McKimmie, Ancelin, Hicks, Amelia J., Hill, Regina, Romero, Lorena, Ponsford, Jennie L., Lannin, Natasha A., Gabbe, Belinda J., Cameron, Peter A., Cooper, D. Jamie, Rushworth, Nick, Fitzgerald, Melinda, O'Brien, Terence J., Alexander, Tara, Anderson, Vicki, Armstrong, Elizabeth, Babl, Franz E., Balogh, Zsolt J., Barlow, Karen M. (AUS-TBI Initiative Investigators group member), Bellapart, Judith, Bidargaddi, Niranjan, Bosio, Erika, Bragge, Peter, Bynevelt, Michael, Caeyenberghs, Karen ... Zeeman, Heidi (2024). The Australian traumatic brain injury initiative: systematic review and consensus process to determine the predictive value of pre-existing health conditions for people with moderate-severe traumatic brain injury. Journal of Neurotrauma. doi: 10.1089/neu.2023.0462

The Australian traumatic brain injury initiative: systematic review and consensus process to determine the predictive value of pre-existing health conditions for people with moderate-severe traumatic brain injury

2024

Journal Article

Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial

Hofman, Michael S., Emmett, Louise, Sandhu, Shahneen, Iravani, Amir, Buteau, James P., Joshua, Anthony M., Goh, Jeffrey C., Pattison, David A., Tan, Thean Hsiang, Kirkwood, Ian D., Ng, Siobhan, Francis, Roslyn J., Gedye, Craig, Rutherford, Natalie K., Weickhardt, Andrew, Scott, Andrew M., Lee, Sze-Ting, Kwan, Edmond M., Azad, Arun A., Ramdave, Shakher, Redfern, Andrew D., Macdonald, William, Guminski, Alex, Hsiao, Edward, Chua, Wei, Lin, Peter, Zhang, Alison Yan, Stockler, Martin R., Williams, Scott G. ... Yip, Sonia (2024). Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial. The Lancet Oncology, 25 (1), 99-107. doi: 10.1016/s1470-2045(23)00529-6

Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial

2024

Journal Article

The impact of fluorine-18-fluoroethyltyrosine positron emission tomography scan timing on radiotherapy planning in newly diagnosed patients with glioblastoma

Ryan, John, Hardcastle, Nicholas, Francis, Roslyn, Ferjančič, Peter, Ng, Sweet Ping, Koh, Eng-Siew, Geso, Moshi, Kelly, Jennifer and Ebert, Martin A. (2024). The impact of fluorine-18-fluoroethyltyrosine positron emission tomography scan timing on radiotherapy planning in newly diagnosed patients with glioblastoma. Physics and Imaging in Radiation Oncology, 29 100536, 100536. doi: 10.1016/j.phro.2024.100536

The impact of fluorine-18-fluoroethyltyrosine positron emission tomography scan timing on radiotherapy planning in newly diagnosed patients with glioblastoma

2024

Journal Article

The Australian traumatic brain injury initiative: systematic review and consensus process to determine the predictive value of demographic, injury event, and social characteristics on outcomes for people with moderate-severe traumatic brain injury

Gabbe, Belinda J., Keeves, Jemma, Mckimmie, Ancelin, Gadowski, Adelle M., Holland, Andrew J., Semple, Bridgette D., Young, Jesse T., Crowe, Louise, Ownsworth, Tamara, Bagg, Matthew K., Antonic-Baker, Ana, Hicks, Amelia J., Hill, Regina, Curtis, Kate, Romero, Lorena, Ponsford, Jennie L., Lannin, Natasha A., O'brien, Terence J., Cameron, Peter A., Cooper, Jamie, Rushworth, Nick, Fitzgerald, Melinda, Alexander, Tara, Anderson, Vicki, Armstrong, Elizabeth, Babl, Franz E., Balogh, Zsolt J., Barlow, Karen M. (AUS-TBI Initiative Investigators member), Bellapart, Judith ... Honeybul, Stephen (2024). The Australian traumatic brain injury initiative: systematic review and consensus process to determine the predictive value of demographic, injury event, and social characteristics on outcomes for people with moderate-severe traumatic brain injury. Journal of Neurotrauma. doi: 10.1089/neu.2023.0461

The Australian traumatic brain injury initiative: systematic review and consensus process to determine the predictive value of demographic, injury event, and social characteristics on outcomes for people with moderate-severe traumatic brain injury

2023

Journal Article

Prospective inter-and intra-tracer repeatability analysis of radiomics features in [68Ga]Ga-PSMA-11 and [18F]F-PSMA-1007 PET scans in metastatic prostate cancer

Kendrick, Jake, Francis, Roslyn J., Hassan, Ghulam Mubashar, Rowshanfarzad, Pejman, Ong, Jeremy S.L., Jeraj, Robert, Barry, Nathaniel, Hagan, Tammy and Ebert, Martin A. (2023). Prospective inter-and intra-tracer repeatability analysis of radiomics features in [68Ga]Ga-PSMA-11 and [18F]F-PSMA-1007 PET scans in metastatic prostate cancer. British Journal of Radiology, 96 (1152) 20221178, 1-11. doi: 10.1259/bjr.20221178

Prospective inter-and intra-tracer repeatability analysis of radiomics features in [68Ga]Ga-PSMA-11 and [18F]F-PSMA-1007 PET scans in metastatic prostate cancer

2023

Journal Article

Quantitative [68Ga]Ga-PSMA-11 PET biomarkers for the analysis of lesion-level progression in biochemically recurrent prostate cancer: a multicentre study

Kendrick, Jake, Francis, Roslyn J., Hassan, Ghulam Mubashar, Rowshanfarzad, Pejman, Ong, Jeremy S. L., Barry, Nathaniel, Rusanov, Branimir and Ebert, Martin A. (2023). Quantitative [68Ga]Ga-PSMA-11 PET biomarkers for the analysis of lesion-level progression in biochemically recurrent prostate cancer: a multicentre study. Scientific Reports, 13 (1) 17673, 17673. doi: 10.1038/s41598-023-45106-2

Quantitative [68Ga]Ga-PSMA-11 PET biomarkers for the analysis of lesion-level progression in biochemically recurrent prostate cancer: a multicentre study

2023

Journal Article

Prognostic utility of RECIP 1.0 with manual and AI-based segmentations in biochemically recurrent prostate cancer from [68Ga]Ga-PSMA-11 PET images

Kendrick, Jake, Francis, Roslyn J., Hassan, Ghulam Mubashar, Rowshanfarzad, Pejman, Ong, Jeremy S. L., McCarthy, Michael, Alexander, Sweeka and Ebert, Martin A. (2023). Prognostic utility of RECIP 1.0 with manual and AI-based segmentations in biochemically recurrent prostate cancer from [68Ga]Ga-PSMA-11 PET images. European Journal of Nuclear Medicine and Molecular Imaging, 50 (13), 4077-4086. doi: 10.1007/s00259-023-06382-2

Prognostic utility of RECIP 1.0 with manual and AI-based segmentations in biochemically recurrent prostate cancer from [68Ga]Ga-PSMA-11 PET images

2023

Journal Article

Improved arterial inflammation with high dose omega-3 fatty acids in patients with elevated lipoprotein(a): selective effect of eicosapentaenoic acid?

Ward, Natalie C., Ying, Qidi, Chan, Dick C., Pang, Jing, Mori, Trevor A., Schultz, Carl J., Dwivedi, Girish, Francis, Roslyn J. and Watts, Gerald F. (2023). Improved arterial inflammation with high dose omega-3 fatty acids in patients with elevated lipoprotein(a): selective effect of eicosapentaenoic acid?. Journal of Clinical Lipidology, 17 (5), 694-699. doi: 10.1016/j.jacl.2023.08.004

Improved arterial inflammation with high dose omega-3 fatty acids in patients with elevated lipoprotein(a): selective effect of eicosapentaenoic acid?